Global
Transfection Technology Market: Overview
Transfection
is a process that involves production of genetically modified cells
with the delivery of foreign nucleic acid (DNA or RNA) into the cell.
There are two types of transfection technologies that include stable
and transient. While stable transfection is permanent and the genes
are continually expressed even after the host cell replicates,
transient transfected genes are expressed for a limited period of
time and are not integrated into the host genome. Increasing
prevalence of cancer and growing obese population drives the global
transfection technology market. In addition, initiatives taken by
various government organizations also further accentuates the growth
of this market. The global transfection technology market was valued
at USD 386.4 million in 2012 and is expected to grow at a CAGR of
9.7% from 2013 to 2019, to reach an estimated value of USD 768.2
million by 2019.
Transfection
technologymarket is segmented mainly by types of method and
application. The method segment of the market is classified as
reagent-based method, instrument-based method and virus-based method.
The reagent-based method is further segmented as lipid mediated
transfection (Lipofection), calcium phosphate, cationic polymers,
DEAE-dextran, activated dendrimers and magnetic beads. Reagent based
transfection technology market is experiencing significant growth
owing to cost effectiveness and less complicated methods involved
during transfection. Likewise, instrument-based method includes
electroporation, biolistic technology, microinjection and
laserfection.Instrument-based methods are less time consuming and
accurate;these advantages drive the growth of this segment.
Browse
Market Research
Report:
http://www.transparencymarketresearch.com/transfection-technology.html
http://www.transparencymarketresearch.com/transfection-technology.html
Global
Transfection Technology Market, by Geography
North
America contributed the largest share, i.e.over 45%, in 2012 of the
global transfection technology market. Increasing awareness about
transfection applications and various government initiativesare the
major factorsdriving the growth of transfection technology market in
North America.For instance, in February 2012, National Cancer
Institute (NCI) signed a research agreement with Polypus Transfection
S.A., a France-based, privately-held company. This agreement includes
Polyethylenimine (PEI) reagent from Polypus Transfection S.A that
will be utilized by the National Cancer Institute for in-vitro
transfection exploration to produce transfected proteins, viruses and
antibodies.Europe contributed the second largest share of the total
market in 2012.Utilization of nanomedicine in diagnostics, targeted
drug delivery, clinical trials and drug development studies is on the
peak in Europe. Transfection technologies and reagents are combined
with nanoparticles for better efficacy in the above mentioned
studies. For instance, the European Commission published in 2011 that
it had funded around 200 projects which include utilization of
nanomedicine in research and development under sixth and seventh
framework program.The Asia-Pacific region is expected to witness the
fastest growth (CAGR – more than 10%)due to increasing prevalence
of infectious diseases and utilization of biopharmaceuticals for drug
discovery and development.
Fill
the form for an exclusive sample of this report:
No comments:
Post a Comment